Seeking Alpha

Gilead Sciences (GILD) says the FDA has approved StribildT, a complete once-daily single tablet...

Gilead Sciences (GILD) says the FDA has approved StribildT, a complete once-daily single tablet regimen for HIV-1 infection for treatment-naive adults. The drug - once referred to as the "Quad" prior to FDA approval - is a co-formulated HIV medicine that simplifies therapy by combining four compounds into one daily tablet. Shares +0.7% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs